Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-002323
Filing Date
2023-02-09
Accepted
2023-02-09 16:01:20
Documents
61
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q meip-20221231.htm   iXBRL 10-Q 1836698
2 EX-31.1 meip-ex31_1.htm EX-31.1 19956
3 EX-31.2 meip-ex31_2.htm EX-31.2 19791
4 EX-32.1 meip-ex32_1.htm EX-32.1 14530
5 GRAPHIC img103162763_0.jpg GRAPHIC 42737
  Complete submission text file 0000950170-23-002323.txt   7927321

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT meip-20221231.xsd EX-101.SCH 47668
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT meip-20221231_lab.xml EX-101.LAB 428494
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT meip-20221231_pre.xml EX-101.PRE 320638
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT meip-20221231_def.xml EX-101.DEF 252864
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT meip-20221231_cal.xml EX-101.CAL 36908
55 EXTRACTED XBRL INSTANCE DOCUMENT meip-20221231_htm.xml XML 1630308
Mailing Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130
Business Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130 858-369-7100
MEI Pharma, Inc. (Filer) CIK: 0001262104 (see all company filings)

EIN.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-50484 | Film No.: 23606089
SIC: 2834 Pharmaceutical Preparations